Atlanta Capital Management Co. L L C trimmed its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 3.2% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 142,239 shares of the medical instruments supplier’s stock after selling 4,720 shares during the quarter. Atlanta Capital Management Co. L L C owned approximately 0.71% of ICU Medical worth $24,536,000 as of its most recent filing with the SEC.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. increased its position in shares of ICU Medical by 0.6% during the second quarter. BlackRock Inc. now owns 1,780,976 shares of the medical instruments supplier’s stock worth $307,218,000 after purchasing an additional 11,046 shares in the last quarter. Janus Capital Management LLC grew its holdings in ICU Medical by 178.8% in the 1st quarter. Janus Capital Management LLC now owns 1,439,864 shares of the medical instruments supplier’s stock valued at $219,864,000 after buying an additional 923,395 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in ICU Medical in the 2nd quarter valued at $247,072,000. Vanguard Group Inc. grew its holdings in ICU Medical by 16.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,304,282 shares of the medical instruments supplier’s stock valued at $224,989,000 after buying an additional 183,133 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in ICU Medical by 12.1% in the 1st quarter. Wellington Management Group LLP now owns 652,897 shares of the medical instruments supplier’s stock valued at $99,697,000 after buying an additional 70,283 shares in the last quarter. Hedge funds and other institutional investors own 78.13% of the company’s stock.
ICUI has been the subject of several analyst reports. BidaskClub upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday, June 17th. Sidoti cut ICU Medical from a “buy” rating to a “neutral” rating in a report on Tuesday, June 20th. Zacks Investment Research upgraded ICU Medical from a “hold” rating to a “strong-buy” rating and set a $195.00 target price for the company in a report on Wednesday, July 12th. Finally, Gabelli restated a “buy” rating on shares of ICU Medical in a report on Friday, August 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $193.00.
TRADEMARK VIOLATION NOTICE: This piece was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://sportsperspectives.com/2017/10/11/atlanta-capital-management-co-l-l-c-reduces-position-in-icu-medical-inc-icui.html.
Shares of ICU Medical, Inc. (NASDAQ:ICUI) remained flat at $188.55 during mid-day trading on Wednesday. 20,175 shares of the company’s stock were exchanged. The stock’s 50-day moving average price is $180.38 and its 200-day moving average price is $168.02. ICU Medical, Inc. has a 1-year low of $127.00 and a 1-year high of $192.65. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of 74.23 and a beta of 0.35.
ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.58 by ($0.06). ICU Medical had a return on equity of 7.56% and a net margin of 6.10%. The company had revenue of $331.51 million during the quarter, compared to analyst estimates of $318.30 million. During the same period last year, the firm earned $1.15 earnings per share. The business’s revenue was up 242.8% compared to the same quarter last year. On average, analysts anticipate that ICU Medical, Inc. will post $4.11 earnings per share for the current year.
In other news, Director Joseph R. Saucedo sold 9,000 shares of the business’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $189.46, for a total value of $1,705,140.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert S. Swinney sold 4,477 shares of the business’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $175.00, for a total value of $783,475.00. Following the completion of the transaction, the director now directly owns 23,293 shares of the company’s stock, valued at $4,076,275. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,524 shares of company stock valued at $4,070,354. Insiders own 15.90% of the company’s stock.
ICU Medical Company Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.